Drug intelligence / Profile preview

ProV-001

Development stage: Preclinical
Lead developer: Progeneer
Modality: Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

ProV-001 is an idiotype cancer vaccine being developed by Progeneer for the treatment of B-cell lymphoma. It is designed to elicit a targeted immune response against the tumor-specific immunoglobulin idiotype, a unique protein sequence found on the surface of malignant B cells that acts as a neoantigen. By training the immune system to recognize this specific idiotype, the vaccine aims to selectively eliminate lymphoma cells while sparing healthy tissues. The program is currently in the IND-enabling stage, undergoing GLP toxicology studies to support future clinical trials.

Targets

Id (Tumor-specific idiotype immunoglobulin)

Beyond the preview

Go deeper on ProV-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProV-001.

Explore the full profile